Adaptive Biotechnologies Corporation provided revenue guidance for the first quarter ended March 31, 2024. For the period, total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.72 USD | -4.62% | +4.49% | -24.08% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.08% | 548M | |
-29.78% | 9.59B | |
-2.96% | 3.21B | |
+28.23% | 2.92B | |
-14.73% | 2.15B | |
-15.05% | 1.79B | |
+69.62% | 1.47B | |
+23.08% | 770M | |
-2.84% | 761M | |
+5.37% | 316M |
- Stock Market
- Equities
- ADPT Stock
- News Adaptive Biotechnologies Corporation
- Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024